Amplia Therapeutics Ltd. ( (AU:ATX) ) has provided an announcement.
Amplia Therapeutics Limited has initiated trial activities for a new pancreatic cancer treatment in the US, combining their FAK inhibitor narmafotinib with the chemotherapy FOLFIRINOX. The trial, managed by a multinational CRO, aims to assess the safety, tolerability, and efficacy of this combination in advanced pancreatic cancer patients, potentially enhancing treatment outcomes and strengthening Amplia’s position in the oncology field.
More about Amplia Therapeutics Ltd.
Amplia Therapeutics Limited is an Australian pharmaceutical company specializing in the development of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis, with a particular focus on fibrotic cancers such as pancreatic cancer.
YTD Price Performance: 17.50%
Average Trading Volume: 19,116
Technical Sentiment Signal: Strong Buy
Current Market Cap: $14M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.